B02BD05 - 검색 결과

recombinate 500 iu

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

이스라엘 - 영어 - Ministry of Health

eloctate 1000

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 1000 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

이스라엘 - 영어 - Ministry of Health

eloctate 250

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 250 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

이스라엘 - 영어 - Ministry of Health

eloctate 500

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 500 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children 12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.